Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial

Pharmacological Research

Volumn 99, Issue , 2015, Pages 74-81

  Chen, Shihui ^a,c   Zhao, Xiaolan ^b   Wan, Jing ^a   Ran, Li ^a   Qin, Yu ^a   Wang, Xiaofang ^b   Gao, Yanxiang ^a   Shu, Furong ^a   Zhang, Yong ^a   Liu, Peng ^a   Zhang, Qianyong ^a   Zhu, Jundong ^a   Mi, Mantian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHWEST HOSPITAL   (China)

^c Foshan Hospital of Traditional Chinese Medicine   (China)

Author keywords

Cytokeratin 18 fragment; Dihydromyricetin; Fibroblast growth factor 21; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; DIHYDROMYRICETIN; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYRICETIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FLAVONOL DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID COMPOSITION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TREATMENT OUTCOME; AMPELOPSIS; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ISOLATION AND PURIFICATION; MEDICINAL PLANT; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AMPELOPSIS; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; FLAVONOLS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLANTS, MEDICINAL;

EID: 84930681002     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.009     Document Type: Article

References (48)

1. G.C. Farrell, and C.Z. Larter Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 2006 S99 S112
2. D.J. Chiang, M.T. Pritchard, and L.E. Nagy Obesity, diabetes mellitus, and liver fibrosis Am. J. Physiol. Gastrointest. Liver Physiol. 300 2011 G697 G702
3. G. Rodriguez, S. Gallego, C. Breidenassel, L.A. Moreno, and F. Gottrand Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents Nutr. Hosp. 25 2010 712 717
4. M.A. Ibrahim, M. Kelleni, and A. Geddawy Nonalcoholic fatty liver disease: current and potential therapies Life Sci. 92 2013 114 118
5. J.G. Fan, and G.C. Farrell Epidemiology of non-alcoholic fatty liver disease in china J. Hepatol. 50 2009 204 210
6. L. Peng, J. Wang, and F. Li Weight reduction for non-alcoholic fatty liver disease Cochrane Database Syst. Rev. 2011 CD003619
7. A.J. McCullough Pathophysiology of nonalcoholic steatohepatitis J. Clin. Gastroenterol. 40 Suppl. 1 2006 S17 S29
8. S. Chitturi, G. Farrell, L. Frost, A. Kriketos, R. Lin, C. Fung, C. Liddle, D. Samarasinghe, and J. George Serum leptin in nash correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity Hepatology 36 2002 403 409
9. Q.M. Anstee, and R.D. Goldin Mouse models in non-alcoholic fatty liver disease and steatohepatitis research Int. J. Exp. Pathol. 87 2006 1 16
10. J. Gao, B. Liu, Z. Ning, R. Zhao, A. Zhang, and Q. Wu Characterization and antioxidant activity of flavonoid-rich extracts from leaves of Ampelopsis grossedentata J. Food Biochem. 33 2009 808 820
11. Xu Jingjuan, Yao Maojun, and X. Gang Study on antioxidant activities of dihydromyricetin Food Sci. 28 2007 43 45
12. Y. Zhou, F. Shu, X. Liang, H. Chang, L. Shi, X. Peng, J. Zhu, and M. Mi Ampelopsin induces cell growth inhibition and apoptosis in breast cancer cells through ros generation and endoplasmic reticulum stress pathway PLoS ONE 9 2014 e89021
13. L. Yushan Effects of enshi-ampelopsis grossede on serum lipid and blood rheology and oxygen free radical of hyperlipidemia model rats J. Hubei Inst. Natl. Med. Ed. 23 2006 7 9
14. Y. Chen, D. Ni, Q. Cheng, H. Huang, Y. Meng, and W. Moucheng Study on the hypolipidemic effect of flavones and dihydromyricetin from tengcha J. Tea Sci. 27 2007 221 225
15. J. Qin, Z. Zhong, G. Zhou, and X. Chen The experimental studies of dihydromyricetin on antidiabetic effect Chin. J. Mod. Appl. Pharm. 18 2001 351 352
16. D. Zou, K. Chen, P. Liu, H. Chang, J. Zhu, and M. Mi Dihydromyricetin improves physical performance under simulated high altitude Med. Sci. Sports Exerc. 46 2014 2077 2084
17. L. Shi, T. Zhang, X. Liang, Q. Hu, J. Huang, Y. Zhou, M. Chen, Q. Zhang, J. Zhu, and M. Mi Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the ampk signaling pathway Mol. Cell. Endocrinol. 409 July 2015 92 102 10.1016/j.mce.2015.03.009 Epub 2015 Mar 20
18. J. Xu, M. Yao, and M. Wu Study on biological efficacy of dihydromyricetin Food Sci. 29 2008 622 625
19. P. Tan, M. Yao, Y. Xin, and M. MA Study on acute toxicological evaluation of ethanol extracts from fusty tea Food Mach. 27 101-102 2011 106
20. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J. 22 2008 659 661
21. R.M. van Dam, N. Naidoo, and R. Landberg Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings Curr. Opin. Lipidol. 24 2013 25 33
22. M. Chiloiro, M.G. Caruso, A.M. Cisternino, R. Inguaggiato, R. Reddavide, C. Bonfiglio, V. Guerra, M. Notarnicola, G. De Michele, M. Correale, M.R. Noviello, and G. Misciagna Ultrasound evaluation and correlates of fatty liver disease: a population study in a mediterranean area Metab. Syndr. Relat. Disord. 11 2013 349 358
23. R. Anty, S. Marjoux, and A. Iannelli Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery J. hepatol. 57 2012 1090 1096
24. T. Murakami, M. Miyakoshi, D. Araho, K. Mizutani, T. Kambara, T. Ikeda, W.-H. Chou, M. Inukai, A. Takenaka, and K. Igarashi Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin Biofactors 21 2004 175 178
25. J.W. Haukeland, Z. Konopski, H.B. Eggesbo, H.L. von Volkmann, G. Raschpichler, K. Bjoro, T. Haaland, E.M. Loberg, and K. Birkeland Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial Scand. J. Gastroenterol. 44 2009 853 860
26. R. Loomba, G. Lutchman, D.E. Kleiner, M. Ricks, J.J. Feld, B.B. Borg, A. Modi, P. Nagabhyru, A.E. Sumner, T.J. Liang, and J.H. Hoofnagle Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis Aliment. Pharmacol. Ther. 29 2009 172 182
27. V. Ratziu, F. Charlotte, C. Bernhardt, P. Giral, M. Halbron, G. Lenaour, A. Hartmann-Heurtier, E. Bruckert, T. Poynard, and L.S. Group Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (flirt 2) extension trial Hepatology 51 2010 445 453
28. K. Kargiotis, N. Katsiki, V.G. Athyros, O. Giouleme, K. Patsiaoura, E. Katsiki, D.P. Mikhailidis, and A. Karagiannis Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report Curr. Vasc. Pharmacol. 12 2014 505 511
29. D. Shyangdan, C. Clar, N. Ghouri, R. Henderson, T. Gurung, D. Preiss, N. Sattar, A. Fraser, and N. Waugh Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review Health Technol. Assess. 15 2011 1 110
30. P.V. Babu, D. Liu, and E.R. Gilbert Recent advances in understanding the anti-diabetic actions of dietary flavonoids J. Nutr. Biochem. 24 2013 1777 1789
31. J.M. Hui, A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, and J. George Beyond insulin resistance in nash: Tnf-alpha or adiponectin Hepatology 40 2004 46 54
32. M.H. Jarrar, A. Baranova, R. Collantes, B. Ranard, M. Stepanova, C. Bennett, Y. Fang, H. Elariny, Z. Goodman, V. Chandhoke, and Z.M. Younossi Adipokines and cytokines in non-alcoholic fatty liver disease Aliment. Pharmacol. Ther. 27 2008 412 421
33. N. Xianjuan Kou Chen Pharmacological potential of ampelopsin in rattan tea Food Sci. Hum. Wellness 1 2012 14 18
34. A.E. Feldstein, A. Wieckowska, A.R. Lopez, Y.C. Liu, N.N. Zein, and A.J. McCullough Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study Hepatology 50 2009 1072 1078
35. D.L. Diab, L. Yerian, P. Schauer, S.R. Kashyap, R. Lopez, S.L. Hazen, and A.E. Feldstein Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients Clin. Gastroenterol. Hepatol. 6 2008 1249 1254
36. A. Wieckowska, N.N. Zein, L.M. Yerian, A.R. Lopez, A.J. McCullough, and A.E. Feldstein In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 44 2006 27 33
37. Y.N. Tetsuya Nishimura, Morichika Konishi, and Itoh. Nobuyuki Identification of a novel fgf,fgf-21, preferentially expressed in the liver Biochim. Biophys. Acta 1492 2000 203 206
38. H. Li, Q. Fang, F. Gao, J. Fan, J. Zhou, X. Wang, H. Zhang, X. Pan, Y. Bao, K. Xiang, and A.W.J. Xu Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride J. Hepatol. 53 2010 934 940
39. T. Reinehr, J. Woelfle, R. Wunsch, and C.L. Roth Fibroblast growth factor 21 (fgf-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis J. Clin. Endocrinol. Metab. 97 2012 2143 2150
40. J. Dushay, P.C. Chui, G.S. Gopalakrishnan, M. Varela-Rey, M. Crawley, F.M. Fisher, M.K. Badman, M.L. Martinez-Chantar, and E. Maratos-Flier Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease Gastroenterology 139 2010 456 463
41. Y. Yilmaz, F. Eren, O. Yonal, R. Kurt, B. Aktas, C.A. Celikel, O. Ozdogan, N. Imeryuz, C. Kalayci, and E. Avsar Increased serum fgf21 levels in patients with nonalcoholic fatty liver disease Eur. J. Clin. Investig. 40 2010 887 892
42. H. Yan, M. Xia, X. Chang, Q. Xu, H. Bian, M. Zeng, S. Rao, X. Yao, Y. Tu, W. Jia, and X. Gao Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study PLoS ONE 6 2011 e24895
43. G. Morris-Stiff, and A.E. Feldstein Fibroblast growth factor 21 as a biomarker for nafld: integrating pathobiology into clinical practice J. Hepatol. 53 2010 795 796
44. J. Shen, H.L. Chan, G.L. Wong, P.C. Choi, A.W. Chan, H.Y. Chan, A.M. Chim, D.K. Yeung, F.K. Chan, J. Woo, J. Yu, W.C. Chu, and V.W. Wong Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers J. Hepatol. 56 2012 1363 1370
45. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T. Brozinick, E.D. Hawkins, V.J. Wroblewski, D.S. Li, F. Mehrbod, S.R. Jaskunas, and A.B. Shanafelt Fgf-21 as a novel metabolic regulator J. Clin. Invest. 115 2005 1627 1635
46. G. Gaich, J.Y. Chien, H. Fu, L.C. Glass, M.A. Deeg, W.L. Holland, A. Kharitonenkov, T. Bumol, H.K. Schilske, and D.E. Moller The effects of ly2405319, an fgf21 analog, in obese human subjects with type 2 diabetes Cell Metab. 18 2013 333 340
47. D. Joy, V.R. Thava, and B.B. Scott Diagnosis of fatty liver disease: is biopsy necessary Eur. J. Gastroenterol. Hepatol. 15 2003 539 543
48. C.D. Williams, J. Stengel, M.I. Asike, D.M. Torres, J. Shaw, M. Contreras, C.L. Landt, and S.A. Harrison Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 2011 124 131